Loading…
5 companies · GEL, thousands · columns ordered by revenue
GEL, thousands · money Σ · ratios from summed bases · growth on the pooled series
| Metric | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|
| Revenue | 9,381 | 5,268 | 6,047 | 7,286 |
| EBITDA | 4,174 | 2,306 | 1,170 | 2,027 |
| Net profit | 4,426 | -506 | -1,244 | 1,103 |
| Total assets | 5,987 | 45,638 | 45,778 | 46,075 |
| n (companies reporting) | 2 | 4 | 4 | 4 |
GEL, thousands
| Company | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|
| G.natadzis Sakhelobis S… | — | 0 | 1,892 | 1,907 |
| Kromosi | — | 0 | 763 | 1,844 |
| TL Medikal | 1,864 | 2,051 | 1,588 | 1,769 |
| Medlab 2024 | — | — | — | 1,766 |
| Medi Praim | 7,517 | 3,217 | 1,804 | — |
Rows are the raw pool — every peer, including any excluded from the sums above, so the de-duplication stays auditable. Tinted cells are the excluded company-years.
Peer coverage varies by year — FY2021–FY2024 pool fewer than the 5 picked companies (see the n row). A year is never dropped because one peer is missing.
Pooled figures sum every peer in the set. Known parent/subsidiary groups that file separately are de-duplicated; groups not yet curated may still be counted more than once.